search
Back to results

Milk Protein and Bone Health in Postmenopausal Women (OSTEOMILK)

Primary Purpose

Bone and Bones, Osteoporosis Risk, Osteoporosis, Postmenopausal

Status
Completed
Phase
Not Applicable
Locations
Ireland
Study Type
Interventional
Intervention
Milk-based protein matrix (MBPM)
Habitual dietary behaviour
Sponsored by
University of Limerick
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Bone and Bones focused on measuring Osteoporosis, Postmenopausal, Bone Turnover Markers, Dairy Products

Eligibility Criteria

50 Years - 70 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Post-menopausal women aged 50-70y. Assessed by site-specific BMD to be osteopenic. Assessed by clinical screen to be otherwise healthy and free from other illness or current medication likely to influence the study outcome.

Exclusion Criteria:

  • Intolerance to dairy-based food products

Sites / Locations

  • University of Limerick

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Other

Arm Label

Milk-based protein matrix (MBPM)

CONTROL

Arm Description

Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.

Intervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover

Outcomes

Primary Outcome Measures

Aerial Bone Mineral Density (BMD)
Site specific (hip and lumbar) BMD measured by Dual Energy X-ray Absorptiometry (DXA)

Secondary Outcome Measures

Bone Resorption
Measured by biomarkers of bone resorption in fasting blood, i.e. C-terminal telopeptide of type I collagen (CTX, ng/ml), and diurnal (24h) urinary deoxypyridinoline (DPD, nmol/mmol creatinine) and N-terminal telopeptide of type I collagen (NTX, nmol/mmol creatinine) excretion normalised for urinary creatinine.
Bone Formation
Measured by a biomarker of bone formation in fasting blood, i.e. serum pro-collagen type 1 N-terminal propeptide (P1NP, ng/ml)

Full Information

First Posted
September 28, 2018
Last Updated
April 29, 2021
Sponsor
University of Limerick
Collaborators
Dairygold Cooperative Society
search

1. Study Identification

Unique Protocol Identification Number
NCT03701113
Brief Title
Milk Protein and Bone Health in Postmenopausal Women
Acronym
OSTEOMILK
Official Title
Evaluation of a Milk-Based Protein Supplement to Effect a Positive Change in Bone Health in Post-Menopausal Women Aged 50 to 70 y at Risk of Osteoporosis
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
October 22, 2018 (Actual)
Primary Completion Date
July 30, 2019 (Actual)
Study Completion Date
July 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Limerick
Collaborators
Dairygold Cooperative Society

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The process of bone remodeling exhibits pronounced diurnal pattern that is important for bone health. A balanced rate of bone resorption is required to maintain bone health, a balance that can be disturbed during the life-cycle to effect net rate of formation (as occurs during growth and development to adulthood) or net resorption (as occurs, for example, during the menopause). Bone turnover is a nutritionally modulated process and the investigators believe a milk-based protein supplement (MBPS) can modulate beneficially the rate of bone resorption over the time period when bone remodeling is most active i.e. late evening/overnight. In this novel approach to the timing of nutrient ingestion, the proposed nutrient intervention seeks to modify (reduce) the rate of bone resorption and promote the rate of bone formation to the benefit of bone health in this at risk population..
Detailed Description
Study design: A block randomised, controlled study among healthy, post-menopausal women with osteopenia receiving a milk-based protein supplement (MBPS) in the evening, or not,(CONTROL) for a period of 24 weeks. Composition of MBPM - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured. All formulations to be supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland. Participants: 60 Post-menopausal women with osteopenia as determined by site-specific bone mineral density BMD (DXA) diagnosed and screened by a clinician and for dietary intake of calcium and Vit D by a clinical dietitian.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bone and Bones, Osteoporosis Risk, Osteoporosis, Postmenopausal
Keywords
Osteoporosis, Postmenopausal, Bone Turnover Markers, Dairy Products

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A block randomised, controlled study among healthy, post-menopausal women with osteopenia receiving a milk-based protein supplement (MBPS) in the evening, or not (CONTROL), for a period of 24 weeks.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
64 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Milk-based protein matrix (MBPM)
Arm Type
Active Comparator
Arm Description
Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.
Arm Title
CONTROL
Arm Type
Other
Arm Description
Intervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover
Intervention Type
Dietary Supplement
Intervention Name(s)
Milk-based protein matrix (MBPM)
Intervention Description
Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
Habitual dietary behaviour
Intervention Description
Subjects to maintain habitual dietary behaviour for the 24 week intervention
Primary Outcome Measure Information:
Title
Aerial Bone Mineral Density (BMD)
Description
Site specific (hip and lumbar) BMD measured by Dual Energy X-ray Absorptiometry (DXA)
Time Frame
Change from Baseline BMD at 24 weeks
Secondary Outcome Measure Information:
Title
Bone Resorption
Description
Measured by biomarkers of bone resorption in fasting blood, i.e. C-terminal telopeptide of type I collagen (CTX, ng/ml), and diurnal (24h) urinary deoxypyridinoline (DPD, nmol/mmol creatinine) and N-terminal telopeptide of type I collagen (NTX, nmol/mmol creatinine) excretion normalised for urinary creatinine.
Time Frame
Change from Baseline CTX, NTX and DPD at 24 weeks
Title
Bone Formation
Description
Measured by a biomarker of bone formation in fasting blood, i.e. serum pro-collagen type 1 N-terminal propeptide (P1NP, ng/ml)
Time Frame
Change from Baseline P1NP at 24 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Post-menopausal women aged 50-70y. Assessed by site-specific BMD to be osteopenic. Assessed by clinical screen to be otherwise healthy and free from other illness or current medication likely to influence the study outcome. Exclusion Criteria: Intolerance to dairy-based food products
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip M Jakeman, PhD
Organizational Affiliation
University of Limerick
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Limerick
City
Limerick
ZIP/Postal Code
V94 T9PX
Country
Ireland

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
http://ul.ie./4i
Description
Center for Interventions in Inflammation Infection and Immunity
Available IPD and Supporting Information:
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
http://www.ul.ie/ehs/research-ethics
Available IPD/Information Identifier
2018_04_05_EHS
Available IPD/Information Comments
Contact The EHS Research Ethics Contact Point of the Education and Health Sciences Research Ethics Committee, Room E1003, University of Limerick, Limerick, Ireland

Learn more about this trial

Milk Protein and Bone Health in Postmenopausal Women

We'll reach out to this number within 24 hrs